First EASL NAFLD Summit: Diagnosis and pharmacotherapy of NASH

NAFLD is the leading cause of chronic liver disease not only in Western countries but also among developing countries of the Far East, South Asia, the Middle East, and Latin America. In the US and Europe, nearly 40% of the population have NAFLD and approximately 20% of these individuals are likely to develop progressive liver disease (i.e. NASH) that lead to liver fibrosis and cirrhosis. Another emerging challenge is hepatocellular cancer which increasingly arises in precirrhotic stages. Although a significant number of new drugs are already in the development pipeline, none are as yet, approved by regulatory agencies. As such, the identification and development of new therapies is urgently needed.
This summit will cover both the basic and translational / clinical aspects of NAFLD, with a specific focus on novel drug target and prognostic signature development.

-Who Should Attend:
Basic and translational scientists, Clinical researchers, Industry / Biotechnology, Hepatologists, Health professionals, Regulatory and funding agencies, Young researchers and trainees

-Why Attend?
Presentations from Academia and Industry, Dedicated to translational science, Encourage collaboration between Academia and Industry, Identifying future areas for drug development

-Topics to be covered:
NAFLD pathogenesis, patient management, prognostic and therapeutic targets, non-invasive assessment of fibrosis, apoptosis, biomarkers, insulin resistance and signalling, hormonal and bile acids signalling, oxidative and mitochondrial stress, inflammation and immunity in NASH, carcinogenesis, gut microbiota.